Literature DB >> 7820574

Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities.

N C Notermans1, J H Wokke, H M Lokhorst, H Franssen, Y van der Graaf, F G Jennekens.   

Abstract

The natural course of polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS) is not well known. We therefore studied 32 untreated patients for a period of 5 years. Fifteen patients had an IgM M-protein, 15 an IgG and two an IgA. There was a male predominance, a mean age of onset at the end of the sixth decade and sensory signs were more pronounced than motor deficits. On entry into the study and during the 5 years of follow-up, we quantified the neuropathy in a standard way: totals of motor and sensory scores; vibration perception threshold; tapping tests; quantified Romberg test; electrophysiological parameters. A significant difference in the natural history between the polyneuropathy associated with IgM-MGUS and IgG/IgA-MGUS was found for the motor and sensory sum scores, the vibration perception threshold and the tapping tests. The polyneuropathy in IgM-MGUS is more progressive, with significantly more weakness and sensory signs, indicating that the neuropathies associated with IgM-MGUS and IgG/A-MGUS may be two different entities. A rapid progression of the neuropathy was found in five patients. We found no predictive factors for this severe progression of the neuropathy of these five patients. Of these five, three (two IgM, one IgG) developed a non-Hodgkin lymphoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7820574     DOI: 10.1093/brain/117.6.1385

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  17 in total

1.  [Polyneuropathies in monoclonal gammopathy of undetermined significance: initial manifestation of a lymphoma].

Authors:  C Drees; M Grond; B Szelies; M Dietlein; B Salzberger; V Diehl; W D Heiss
Journal:  Med Klin (Munich)       Date:  1997-02-15

2.  Lymphoma, paraproteinaemia, and neuropathy.

Authors:  J H Wokke; J H Morris; M Donaghy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

3.  Response to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy with only sensory symptoms.

Authors:  G W van Dijk; N C Notermans; H Franssen; P L Oey; J H Wokke
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

Review 4.  Neuropathy associated with "benign" anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases.

Authors:  E Ellie; A Vital; A Steck; J M Boiron; C Vital; J Julien
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

5.  Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients.

Authors:  T Maisonobe; B Chassande; M Vérin; M Jouni; J M Léger; P Bouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

6.  Axonal neuropathy associated with monoclonal gammopathy of undetermined significance.

Authors:  K C Gorson; A H Ropper
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

7.  Additional causes for distal sensory polyneuropathy in diabetic patients.

Authors:  K C Gorson; A H Ropper
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

8.  Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial.

Authors:  Allan H Ropper; Kenneth C Gorson; Clifton L Gooch; David H Weinberg; Ann Pieczek; James H Ware; Joshua Kershen; Adam Rogers; Drasko Simovic; Peter Schratzberger; Rudolf Kirchmair; Douglas Losordo
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 9.  Cryptogenic sensory polyneuropathy.

Authors:  Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2013-03-13       Impact factor: 3.806

10.  Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance.

Authors:  Teny Henry Gomez; Beata Holkova; Danielle Noreika; Egidio Del Fabbro
Journal:  BMJ Case Rep       Date:  2016-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.